Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others...
用于治疗革兰阳性菌耐甲氧西林金黄色葡萄球菌(MRSA)与甲氧西林敏感金黄色葡萄球菌引起的成人复杂性皮肤和皮肤结构感染,以及医院获得性和呼吸机相关细菌性肺炎(HABP/VABP)。
Louisiana State University Health Sciences Center, Dept of Med/ER Med, New Orleans, Louisiana, United States
Paradise Valley Hospital, 2400 E. 4th Street, National City, California, United States
Paradise Valley Hospital, 2400 E. 4th Street, National City, California, United States
Wellstar Infectious Disease, Marietta, Georgia, United States
eStudy Site, 3450 Bonita Road, Ste 201, Chula Vista, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.